Latest Articles

Publication Date
Baylen Dupree Confirms Endometriosis Diagnosis After Months of Uncertainty - JubileeCast

Baylen Dupree Confirms Endometriosis Diagnosis After Months of Uncertainty JubileeCast

Published: Aug. 5, 2026, 10:15 a.m.
TREM2 Deficiency Attenuates Endometriosis Progression by Inhibiting M2 Polarization of SpMs and Suppressing SIRPα to Enhance Phagocytosis.

Endometriosis (EMS) is characterised by a disrupted peritoneal immune microenvironment where M2 macrophage polarization and impaired phagocytosis promote lesion survival. Single-cell RNA-seq (ScRNAseq) of the peritoneal macrophages from EMS patient …

Published: Aug. 5, 2026, midnight
Association of Autoimmune Hyperthyroidism and Endometriosis, With an Endometrioma Rupture as a Complication: A Case Report and Review of the Literature.

This case report examines the association between autoimmune thyroid disease, more commonly known as Graves' disease, and endometriosis with a focus on the complication of an endometrioma rupture. The interplay …

Published: Aug. 5, 2026, midnight
Long-term clinical effectiveness of endovenous interventions for pelvic venous disorders.

Endovenous therapies are the current standard of care for the management of pelvic venous disorders (PeVD) secondary to pelvic venous insufficiency. We previously reported superior short-term results after iliac vein …

Published: Aug. 5, 2026, midnight
Hair Relaxer Lawsuit Settlement | August 2026 Litigation Update - Lawsuit Information Center

Hair Relaxer Lawsuit Settlement | August 2026 Litigation Update Lawsuit Information Center

Published: Aug. 4, 2026, 3:46 p.m.
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval - Corsicana Daily Sun

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval Corsicana Daily Sun

Published: Aug. 4, 2026, 1:02 p.m.
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval - Voice of Alexandria

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval Voice of Alexandria

Published: Aug. 4, 2026, 1:02 p.m.
Sunshine Biopharma's 2mg Tablet for Endometriosis Pain Wins Canadian Approval - Stock Titan

Sunshine Biopharma's 2mg Tablet for Endometriosis Pain Wins Canadian Approval Stock Titan

Published: Aug. 4, 2026, 1 p.m.
EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval - Benzinga

EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval Benzinga

Published: Aug. 4, 2026, 12:31 p.m.
Diffuse Adenomyosis Coexisting with rASRM Stage IV Endometriosis in a | IJWH - Dove Medical Press

Diffuse Adenomyosis Coexisting with rASRM Stage IV Endometriosis in a | IJWH Dove Medical Press

Published: Aug. 4, 2026, 9:23 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!